FDA.reportPublic FDA data

caffeine 100 MG / ergotamine tartrate 1 MG Oral Tablet [Cafergot]

RxCUI
1293506
RxNorm name
caffeine 100 MG / ergotamine tartrate 1 MG Oral Tablet [Cafergot]
Display name
CAFERGOT (Oral Pill)
Full name
caffeine 100 MG / ergotamine tartrate 1 MG Oral Tablet [Cafergot]
Term type
SBD
Status
Active
Strength
100-1 mg
Dose form
Tab
Route
Oral Pill
Updated
2026-10-29 06:02:07

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
062012
Active start
062012
Multiple ingredient
YES
Branded
YES

Ingredients And Strength#

Ingredient, Strength, Base table
IngredientStrengthBaseBasis of strength
caffeine100 MG / 1 EACHcaffeinecaffeine
ergotamine tartrate1 MG / 1 EACHergotamineergotamine tartrate

Dose Form Concepts#

Dose form, RxCUI table
Dose formRxCUI
Oral Tablet317541

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
caffeine1886
ergotamine4025

Source Vocabulary Codes#

Code type, Values, Count table
Code typeValuesCountCategory
PRESCRIBABLEY1ATTRIBUTES
RXNAV_STRCafergot (caffeine 100 MG / ergotamine tartrate 1 MG) Oral Tablet1NAMES
RxNorm Namecaffeine 100 MG / ergotamine tartrate 1 MG Oral Tablet [Cafergot]1NAMES
RxNorm SynonymCafergot (caffeine 100 MG / ergotamine tartrate 1 MG) Oral Tablet1NAMES
TTYSBD1ATTRIBUTES
SPL_SET_ID4db7eece-2eef-bc1b-e063-6394a90a98cb1CODES
RxCUI12935061CODES
MMSL_CODEBD14491CODES

FDA NDC Products And Packages#

Package NDC, Product NDC, Name table
Package NDCProduct NDCNameLabelerApplication
73352-917-4073352-917Cafergot ergotamine tartrate and caffeineTrifluent Pharma, LLCANDA040590

Drugs@FDA Applications#

Application, NDC, Name table
ApplicationNDCNameMarketing categoryLabeler
ANDA04059073352-917Cafergot ergotamine tartrate and caffeineANDATrifluent Pharma, LLC

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 8 matching rows.

NDC11, Source, Active table
NDC11SourceActive
00781540501rxnav_ndcsyes
73352091740rxnav_ndcsyes
00078034905rxnav_historical_indirect
00179008970rxnav_historical
00781199501rxnav_historical
00781599501rxnav_historical
55289096012rxnav_historical
63874107203rxnav_historical

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CafergotERGOTAMINE TARTRATE AND CAFFEINETrifluent Pharma, LLC4db7eece-2eef-bc1b-e063-6394a90a98cb2026-03-23Boxed warning, Warnings, Adverse reactionsExact identifier
ndc (package): 73352-917-40
ndc (product): 73352-917
ndc11 (package): 73352091740
rxcui: 1293506

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
4db7eece-2eef-bc1b-e063-6394a90a98cbCafergot 1 MG / 100 MG Oral Tablet [PSN] · caffeine 100 MG / ergotamine tartrate 1 MG Oral Tablet [Cafergot] [SBD] · Cafergot (caffeine 100 MG / ergotamine tartrate 1 MG) Oral Tablet [SY]31Ergotamine Tartrate and Caffeine Tablets, USP 1 mg/100 mg20260323

Recently Linked DailyMed Labels#

Set ID, Title, Manufacturer table
Set IDTitleManufacturerEffective
4db7eece-2eef-bc1b-e063-6394a90a98cbErgotamine Tartrate and Caffeine Tablets, USP 1 mg/100 mgTrifluent Pharma, LLC20260323
b4a06de6-f837-43a8-ae7a-aadb38dd2a7dCafergot® (ergotamine tartrate and caffeine tablets, USP)Sandoz Inc20191216
d286b6ae-299a-4c45-84a1-088d65fe9b6cNational Council for Prescription Drug Programs20120724

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCN02CAErgot alkaloidsATC1-4ergotamine
ATCD11AXOther dermatologicalsATC1-4caffeine
ATCN06BCXanthine derivativesATC1-4caffeine
FDASPLD004879ErgotaminesCHEMhas_chemical_structureergotamine
FDASPLD014970XanthinesCHEMhas_chemical_structurecaffeine
FDASPLN0000175739Central Nervous System StimulantEPChas_epccaffeine
FDASPLN0000175766Ergotamine DerivativeEPChas_epcergotamine
FDASPLN0000175790MethylxanthineEPChas_epccaffeine
FDASPLN0000175729Central Nervous System StimulationPEhas_pecaffeine
MEDRTD001393AzolesCHEMci_chemclassergotamine tartrate
MEDRTD001393AzolesCHEMci_chemclassergotamine
MEDRTD002110CaffeineCHEMhas_ingredientcaffeine
MEDRTD002219CarbamatesCHEMci_chemclassergotamine tartrate
MEDRTD004878ErgotamineCHEMhas_ingredientergotamine
MEDRTD004878ErgotamineCHEMhas_ingredientergotamine tartrate
MEDRTD005663FuransCHEMci_chemclassergotamine tartrate
MEDRTD018942MacrolidesCHEMci_chemclassergotamine tartrate
MEDRTD018942MacrolidesCHEMci_chemclassergotamine
MEDRTD019888NelfinavirCHEMci_chemclassergotamine tartrate
MEDRTD019438RitonavirCHEMci_chemclassergotamine tartrate
MEDRTD013449SulfonamidesCHEMci_chemclassergotamine tartrate
MEDRTD000033Abortion, ThreatenedDISEASEci_withergotamine tartrate
MEDRTD000788Angina Pectoris, VariantDISEASEmay_diagnoseergotamine tartrate
MEDRTD001049ApneaDISEASEmay_treatcaffeine
MEDRTD003027Cluster HeadacheDISEASEmay_treatergotamine tartrate
MEDRTD003027Cluster HeadacheDISEASEmay_treatergotamine
MEDRTD003327Coronary DiseaseDISEASEci_withergotamine tartrate
MEDRTD003327Coronary DiseaseDISEASEci_withergotamine
MEDRTD004342Drug HypersensitivityDISEASEci_withergotamine tartrate
MEDRTD004342Drug HypersensitivityDISEASEci_withergotamine
MEDRTD004342Drug HypersensitivityDISEASEci_withcaffeine
MEDRTD005221FatigueDISEASEmay_treatcaffeine
MEDRTD006973HypertensionDISEASEci_withergotamine
MEDRTD006973HypertensionDISEASEci_withergotamine tartrate
MEDRTD007674Kidney DiseasesDISEASEci_withergotamine tartrate
MEDRTD007674Kidney DiseasesDISEASEci_withergotamine
MEDRTD008107Liver DiseasesDISEASEci_withergotamine
MEDRTD008107Liver DiseasesDISEASEci_withergotamine tartrate
MEDRTD008881Migraine DisordersDISEASEmay_treatergotamine tartrate
MEDRTD008881Migraine DisordersDISEASEmay_treatergotamine
MEDRTD016491Peripheral Vascular DiseasesDISEASEci_withergotamine tartrate
MEDRTD016491Peripheral Vascular DiseasesDISEASEci_withergotamine
MEDRTD006473Postpartum HemorrhageDISEASEmay_preventergotamine tartrate
MEDRTD006473Postpartum HemorrhageDISEASEmay_treatergotamine tartrate
MEDRTD011247PregnancyDISEASEci_withergotamine tartrate
MEDRTD011247PregnancyDISEASEci_withergotamine
MEDRTD018805SepsisDISEASEci_withergotamine tartrate
MEDRTD018805SepsisDISEASEci_withergotamine
MEDRTN0000000209Adrenergic alpha-AgonistsMOAhas_moaergotamine
MEDRTN0000000209Adrenergic alpha-AgonistsMOAhas_moaergotamine tartrate
MEDRTN0000190114Cytochrome P450 3A InhibitorsMOAhas_moaergotamine tartrate
MEDRTN0000190114Cytochrome P450 3A InhibitorsMOAhas_moaergotamine
MEDRTN0000182141Cytochrome P450 3A4 InhibitorsMOAci_moaergotamine
MEDRTN0000182141Cytochrome P450 3A4 InhibitorsMOAci_moaergotamine tartrate
MEDRTN0000000203Dopamine Receptor InteractionsMOAhas_moaergotamine tartrate
MEDRTN0000000203Dopamine Receptor InteractionsMOAhas_moaergotamine
MEDRTN0000000133Enzyme InhibitorsMOAhas_moacaffeine
MEDRTN0000000130Serotonin AntagonistsMOAhas_moaergotamine
MEDRTN0000000130Serotonin AntagonistsMOAhas_moaergotamine tartrate
MEDRTN0000008322BronchodilationPEhas_pecaffeine
MEDRTN0000008331Cardiovascular Activity AlterationPEhas_pecaffeine
MEDRTN0000008351Cerebral Arterial VasoconstrictionPEhas_peergotamine
MEDRTN0000008351Cerebral Arterial VasoconstrictionPEhas_peergotamine tartrate
MEDRTN0000008376Cutaneous Arterial VasoconstrictionPEhas_peergotamine tartrate
MEDRTN0000008567Decreased Collecting Duct Water PermeabilityPEhas_pecaffeine
MEDRTN0000009197Increased Central Nervous System Organized Electrical ActivityPEhas_pecaffeine
MEDRTN0000009705Increased Uterine Smooth Muscle Contraction or TonePEhas_peergotamine tartrate
MEDRTN0000009705Increased Uterine Smooth Muscle Contraction or TonePEhas_peergotamine

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESAVAILABLE_STRENGTH100 MG / 1 MG
ATTRIBUTESGENERAL_CARDINALITYMULTI
ATTRIBUTESHUMAN_DRUGUS
ATTRIBUTESRXNAV_HUMAN_DRUGUS
ATTRIBUTESSCHEDULE0
CODESANDAANDA040590
NAMESPrescribable SynonymCafergot 1 MG / 100 MG Oral Tablet
SOURCESSourceGold Standard Alchemy
SOURCESSourceMetathesaurus FDA Structured Product Labels
SOURCESSourceMicromedex RED BOOK
SOURCESSourceMultum MediSource Lexicon